CARDAX, INC.
CDXI evidence brief
What we can confirm
- BioSniper Score:
- 2.7 / 10
- Market Cap:
- $80
- Lead Asset:
- cdx-101 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for CDXI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$80
Cash Runway
—
Lead Asset
cdx-101 (Preclinical)
Next Catalyst
—
Tracking 1 pipeline candidate for CARDAX, INC..
Run CARDAX, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CARDAX, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is CARDAX, INC.'s lead drug candidate?
CARDAX, INC.'s most advanced tracked candidate is cdx-101 (Preclinical) for cardiovascular inflammation and dyslipidemia.
Who is the CEO of CARDAX, INC.?
Mr. David G. Watumull is the chief executive officer of CARDAX, INC. (CDXI).
Where is CARDAX, INC. headquartered?
CARDAX, INC. (CDXI) is headquartered in Honolulu, HI, United States.
What therapeutic areas does CARDAX, INC. focus on?
CARDAX, INC. develops therapies across Oncology, Ophthalmology, Cardiovascular, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.